%0 Generic
%A Neven, P.
%A Fasching, P. A.
%A Chia, S.
%A Jerusalem, G.
%A De laurentiis, M.
%A Im, S. -A.
%A Petrakova, K.
%A Bianchi, G. V.
%A Martin Jimenez, M.
%A Nusch, A.
%A Sonke, G. S.
%A de la Cruz Merino, L.
%A Beck, J. T.
%A Zarate, J. P.
%A Wang, Y.
%A Chakravartty, A.
%A Wang, C.
%A Slamon, D.
%T Updated overall survival (OS) results from the first-line (1L) population in the phase III MONALEESA-3 trial of postmenopausal patients (PTS) with HR+/HER2-advanced breast cancer (ABC) treated with ribociclib (RIB) plus fulvestrant (FUL)
%D 2022
%@ 0923-7534
%U http://hdl.handle.net/10668/21910
%~